Company Overview - Wave Life Sciences is a biotechnology company focused on developing innovative therapies for genetic diseases, aiming to address unmet medical needs through its proprietary platform [1] - The company operates in a competitive biotech landscape, facing challenges from other firms developing similar therapies [1] Price Target and Stock Performance - On September 4, 2025, Wells Fargo analyst Tiago Fauth set a price target of $18 for NASDAQ:WVE, indicating a potential 75% increase from its trading price of $8 [2][5] - The price target was adjusted down from $21 to $18 following updates on AATD data for the 200 and 400 cohort [2][5] - Currently, WVE is priced at $8.18, reflecting a 2.19% increase with a change of $0.175, and has fluctuated between $7.49 and $8.20 on the same day [4] Market Activity - Over the past year, Wave Life Sciences' stock reached a high of $16.74 and a low of $5.04, with a current market capitalization of approximately $1.3 billion [4] - Today's trading volume for WVE is 3,322,679 shares on the NASDAQ exchange, indicating investor interest possibly influenced by the recent price target adjustment and data updates [4]